NeuroBo Pharmaceuticals Inc. (NRBO) NASDAQ
$3.05 (0.07) (-2.24%)
Market Cap: $15.31M
As of 04/23/24 11:08 AM EDT. Market closed.
NeuroBo Pharmaceuticals Inc. (NRBO)
NASDAQ
$3.05
(0.07) (-2.24%)
Market Cap: $15.31M
As of 04/23/24 11:08 AM EDT. Market closed.
Add to Portfolio
neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
9
URL
Address
.
PRICE CHART FOR NEUROBO PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.16
Previous Close
$3.12
Days Range
$3.08 - $3.26
52 week range
$2.89 - $6.75
Volume
42,194
Avg. Volume (30 days)
29,203
Market Cap
$15.31M
Dividend Yield
-
P/E
-
Shares Outstanding
4,906,032
Open
$3.16
Previous Close
$3.12
Days Range
$3.08 - $3.26
52 week range
$2.89 - $6.75
Volume
42,194
Avg. Volume (30 days)
29,203
Market Cap
$15.31M
Dividend Yield
-
P/E
-
Shares Outstanding
4,906,032
FINANCIAL STATEMENTS FOR NEUROBO PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR NEUROBO PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Reno Seth | Chief Commercial Officer | Feb 08, 2018 | Buy | $7.00 | 14,286 | 100,002 | 18,286 | Feb 12, 2018, 04:40 PM |
| Gullans Steven R. Ph.D. | Interim President & CEO | Feb 08, 2018 | Buy | $7.00 | 71,429 | 500,003 | 930,252 | Feb 12, 2018, 04:31 PM |
| MATHIESEN JEFFREY S | Chief Financial Officer | Aug 14, 2017 | Option Exercise | $3.59 | 3,207 | 11,513 | 14,134 | Aug 16, 2017, 04:10 PM |
| MATHIESEN JEFFREY S | Chief Financial Officer | Aug 10, 2017 | Option Exercise | $3.59 | 3,000 | 10,770 | 10,927 | Aug 15, 2017, 04:22 PM |
| MATHIESEN JEFFREY S | Chief Financial Officer | Aug 10, 2017 | Option Exercise | $3.59 | 3,000 | 10,770 | 10,927 | Aug 11, 2017, 04:07 PM |
| Bisgaier Charles PhD | Chief Scientific Off. & Chair | Jul 31, 2017 | Option Exercise | $1.34 | 4,474 | 6,013 | 1,248,914 | Aug 02, 2017, 04:11 PM |
| SASSINE ANDY | Director | Mar 10, 2017 | Buy | $9.47 | 21,119 | 199,997 | 136,264 | Mar 14, 2017, 06:07 PM |
| LICHTINGER PEDRO | Director | Mar 10, 2017 | Buy | $9.47 | 10,559 | 99,994 | 59,833 | Mar 14, 2017, 05:57 PM |
| Hawryluk P. Kent | Director | Mar 10, 2017 | Buy | $9.47 | 25,000 | 236,750 | 81,889 | Mar 14, 2017, 05:46 PM |
| Gullans Steven R. Ph.D. | Director | Mar 10, 2017 | Buy | $9.47 | 52,798 | 499,997 | 858,823 | Mar 14, 2017, 05:33 PM |
| Hawryluk P. Kent | Director | Aug 10, 2016 | Option Exercise | $6.71 | 23,616 | 158,367 | 31,889 | Aug 12, 2016, 01:27 PM |
| Hawryluk P. Kent | Director | Aug 10, 2016 | Option Exercise | $6.71 | 816 | 5,472 | 8,273 | Aug 12, 2016, 01:27 PM |
| Hawryluk P. Kent | Director | Aug 10, 2016 | Buy | $10.00 | 25,000 | 250,000 | 56,889 | Aug 12, 2016, 01:27 PM |
| SASSINE ANDY | Director | Aug 10, 2016 | Option Exercise | $6.71 | 31,853 | 213,603 | 115,145 | Aug 12, 2016, 01:24 PM |
| SASSINE ANDY | Director | Aug 10, 2016 | Option Exercise | $6.71 | 8,212 | 55,069 | 83,292 | Aug 12, 2016, 01:24 PM |
| LICHTINGER PEDRO | Director | Aug 10, 2016 | Option Exercise | $6.71 | 39,274 | 263,368 | 39,274 | Aug 12, 2016, 01:19 PM |
| LICHTINGER PEDRO | Director | Aug 10, 2016 | Buy | $10.00 | 10,000 | 100,000 | 49,274 | Aug 12, 2016, 01:19 PM |
| KOUSKY KENNETH W | Director | Aug 10, 2016 | Option Exercise | $6.71 | 116,891 | 783,859 | 116,891 | Aug 12, 2016, 01:15 PM |
| KOUSKY KENNETH W | Director | Aug 10, 2016 | Option Exercise | $6.71 | 10,439 | 70,003 | 105,878 | Aug 12, 2016, 01:15 PM |
| KOUSKY KENNETH W | Director | Aug 10, 2016 | Buy | $10.00 | 1,000 | 10,000 | 1,000 | Aug 12, 2016, 01:15 PM |
| Gullans Steven R. Ph.D. | Director | Aug 10, 2016 | Option Exercise | $6.71 | 306,025 | 2,052,173 | 306,025 | Aug 12, 2016, 01:09 PM |
| Gullans Steven R. Ph.D. | Director | Aug 10, 2016 | Buy | $10.00 | 500,000 | 5,000,000 | 806,025 | Aug 12, 2016, 01:09 PM |
| Reno Seth | Chief Commercial Officer | Aug 10, 2016 | Buy | $10.00 | 4,000 | 40,000 | 4,000 | Aug 12, 2016, 01:06 PM |
| Sooch Mina | President & CEO | Aug 10, 2016 | Option Exercise | $6.71 | 27,141 | 182,005 | 39,431 | Aug 12, 2016, 01:01 PM |
| Sooch Mina | President & CEO | Aug 10, 2016 | Option Exercise | $6.71 | 1,212 | 8,128 | 12,290 | Aug 12, 2016, 01:01 PM |
| Sooch Mina | President & CEO | Aug 10, 2016 | Buy | $10.00 | 52,500 | 525,000 | 693,732 | Aug 12, 2016, 01:01 PM |
| Oniciu Carmen Daniela | Vice President | Aug 10, 2016 | Option Exercise | $6.71 | 245 | 1,643 | 152,401 | Aug 12, 2016, 12:56 PM |
| Lowenschuss David | Chief Legal Off. & Secretary | Aug 10, 2016 | Buy | $10.00 | 11,120 | 111,200 | 806,247 | Aug 12, 2016, 12:54 PM |
| MATHIESEN JEFFREY S | Chief Financial Officer | Aug 10, 2016 | Option Exercise | $6.71 | 3,927 | 26,334 | 3,927 | Aug 12, 2016, 12:49 PM |
| MATHIESEN JEFFREY S | Chief Financial Officer | Aug 10, 2016 | Buy | $10.00 | 4,000 | 40,000 | 7,927 | Aug 12, 2016, 12:49 PM |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | Aug 10, 2016 | Option Exercise | $6.71 | 19,228 | 128,941 | 19,228 | Aug 12, 2016, 12:47 PM |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | Aug 10, 2016 | Option Exercise | $6.71 | 16,144 | 108,260 | 82,220 | Aug 12, 2016, 12:47 PM |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | Aug 10, 2016 | Option Exercise | $6.71 | 6,515 | 43,689 | 66,076 | Aug 12, 2016, 12:47 PM |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | Aug 10, 2016 | Buy | $10.00 | 51,750 | 517,500 | 1,244,440 | Aug 12, 2016, 12:47 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Reno Seth | Chief Commercial Officer | 02/08/2018 | 100,002 |
| Gullans Steven R. Ph.D. | Interim President & CEO | 02/08/2018 | 500,003 |
| MATHIESEN JEFFREY S | Chief Financial Officer | 08/14/2017 | 11,513 |
| MATHIESEN JEFFREY S | Chief Financial Officer | 08/10/2017 | 10,770 |
| MATHIESEN JEFFREY S | Chief Financial Officer | 08/10/2017 | 10,770 |
| Bisgaier Charles PhD | Chief Scientific Off. & Chair | 07/31/2017 | 6,013 |
| SASSINE ANDY | Director | 03/10/2017 | 199,997 |
| LICHTINGER PEDRO | Director | 03/10/2017 | 99,994 |
| Hawryluk P. Kent | Director | 03/10/2017 | 236,750 |
| Gullans Steven R. Ph.D. | Director | 03/10/2017 | 499,997 |
| Hawryluk P. Kent | Director | 08/10/2016 | 158,367 |
| Hawryluk P. Kent | Director | 08/10/2016 | 5,472 |
| Hawryluk P. Kent | Director | 08/10/2016 | 250,000 |
| SASSINE ANDY | Director | 08/10/2016 | 213,603 |
| SASSINE ANDY | Director | 08/10/2016 | 55,069 |
| LICHTINGER PEDRO | Director | 08/10/2016 | 263,368 |
| LICHTINGER PEDRO | Director | 08/10/2016 | 100,000 |
| KOUSKY KENNETH W | Director | 08/10/2016 | 783,859 |
| KOUSKY KENNETH W | Director | 08/10/2016 | 70,003 |
| KOUSKY KENNETH W | Director | 08/10/2016 | 10,000 |
| Gullans Steven R. Ph.D. | Director | 08/10/2016 | 2,052,173 |
| Gullans Steven R. Ph.D. | Director | 08/10/2016 | 5,000,000 |
| Reno Seth | Chief Commercial Officer | 08/10/2016 | 40,000 |
| Sooch Mina | President & CEO | 08/10/2016 | 182,005 |
| Sooch Mina | President & CEO | 08/10/2016 | 8,128 |
| Sooch Mina | President & CEO | 08/10/2016 | 525,000 |
| Oniciu Carmen Daniela | Vice President | 08/10/2016 | 1,643 |
| Lowenschuss David | Chief Legal Off. & Secretary | 08/10/2016 | 111,200 |
| MATHIESEN JEFFREY S | Chief Financial Officer | 08/10/2016 | 26,334 |
| MATHIESEN JEFFREY S | Chief Financial Officer | 08/10/2016 | 40,000 |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | 08/10/2016 | 128,941 |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | 08/10/2016 | 108,260 |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | 08/10/2016 | 43,689 |
| Bisgaier Charles PhD | Chair & Chief Scientific Off. | 08/10/2016 | 517,500 |
Load More Insider Transactions
FUNDS WITH A POSITION IN NEUROBO PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 17,332 | 0.00001% | New | Other |
| BLACKROCK INC. | 5,274 | 0% | New | Other |
BUYBACK ANNOUNCEMENT(S) FOR NEUROBO PHARMACEUTICALS INC
LOADING...